Page 17 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 2 ฉบับที่ 3

«“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë Ú ©∫—∫∑’Ë Û ¡‘∂ÿπ“¬π-°—𬓬π ÚıÙ˜ 15

µ“√“ß∑’Ë 9 º≈°“√µ√«®‡π◊ÈÕ‡¬◊ËÕÕ«—¬«–∑“ß®ÿ≈欓∏‘«‘∑¬“¢ÕßÀπŸ·√∑‡æ»ºŸâ∑’ˉ¥â√—∫ºß∫—«∫°

‡ªìπ‡«≈“ 6 ‡¥◊Õπ

¢π“¥¢Õߺß∫—«∫°(¡°./°°./«—π)
Õ«—¬«– °“√‡ª≈’ˬπ·ª≈ß∑’Ëæ∫ 0 20 200 600 1200 1200-R
n=15 n=15 n=15 n=15 n=14 n=14
ªÕ¥ Lymphoid proliferated peribronchioles 13/15 11/15 7/15* 11/15 7/14* 11/14
À—«„® Focal myocardiosis (+1) 0/15 0/15 2/15 4/15 2/14 0/14
µ—∫ Hepatocyte fatty degeneration 5/15 9/15 10/15 8/15 8/14 6/14
Protein cast deposited in sinusoids(+1) 0/15 0/15 0/15 6/15* 7/14* 0/14

°√–‡æ“–Õ“À“√ Submucosal edema with PMN 0/15 0/15 1/15 0/15 0/14 0/14
infiltration
≈”‰ â‡≈Á° Lymphoid aggregated in submucosa 1/15 2/15 2/15 1/15 1/14 5/14
”‰ â„À≠à 4/15 5/15 2/15 3/15 1/14 1/14
Õ—≥±– No remarkable lesion
µàÕ¡À¡«°‰µ Cortical fatty degeneration (+1) 1/15 3/15 8/15* 6/15* 12/14* 4/14

µ—«‡≈¢„πµ“√“ß· ¥ß„π√Ÿª¢Õß ®”π«πÀπŸ∑’˵√«®æ∫欓∏‘ ¿“æ / ®”π«πÀπŸ∑—ÈßÀ¡¥„π°≈ÿà¡
* ·µ°µà“ß®“°°≈ÿࡧ«∫§ÿ¡Õ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘ ∑’Ë p<0.05
+1 À¡“¬∂÷ß °“√‡ª≈’ˬπ·ª≈ßæ∫‡æ’¬ß‡≈Á°πâÕ¬ (mild degree)

µ“√“ß∑’Ë 10 º≈°“√µ√«®‡π◊ÈÕ‡¬◊ËÕÕ«—¬«–∑“ß®ÿ≈欓∏‘«‘∑¬“¢ÕßÀπŸ·√∑‡æ»‡¡’¬∑’ˉ¥â√—∫ºß

∫—«∫°‡ªìπ‡«≈“ 6 ‡¥◊Õπ

¢π“¥¢Õߺß∫—«∫°(¡°./°°./«—π)
Õ«—¬«– °“√‡ª≈’ˬπ·ª≈ß∑’Ëæ∫ 0 20 200 600 1200 1200-R
n=15 n=15 n=15 n=13 n=14 n=14
ªÕ¥ Lymphoid proliferated peribronchioles 8/15 9/15 3/15 8/13 7/14 3/14
°√–‡æ“– Chronic gastritis and mucosal 0/15 0/15 0/15 0/13 1/14 0/14
hyperplasia
µ—∫ Protein cast deposited in sinusoids(+1) 0/15 0/15 2/15 0/13 2/14 0/14
‰µ Chronic pyelititis 0/15 0/15 0/15 1/13 0/14 0/14
Pelvic dilatation 0/15 0/15 1/15 1/13 0/14 0/14
≈”‰ â‡≈Á° Lymphoid aggregated in submucosa 2/15 2/15 4/15 0/13 2/14 5/14
”‰ â„À≠à 5/15 3/15 0/15 5/13 3/14 3/14
µ—«‡≈¢„πµ“√“ß· ¥ß„π√Ÿª¢Õß ®”π«πÀπŸ∑’˵√«®æ∫欓∏‘ ¿“æ / ®”π«πÀπŸ∑—ÈßÀ¡¥„π°≈ÿà¡
* ·µ°µà“ß®“°°≈ÿࡧ«∫§ÿ¡Õ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘ ∑’Ë p<0.05
+1 °“√‡ª≈’ˬπ·ª≈ßæ∫‡æ’¬ß‡≈Á°πâÕ¬ (mild degree)